NKGen Biotech, Inc.

NKGen Biotech, Inc. is a biotechnology company that develops cell therapies for neurodegenerative and oncological diseases. These therapies are based on activated natural killer ("NK") cells, which are part of the human innate immune response system and can identify and destroy abnormal or diseased cells. The company's product candidates utilize a proprietary manufacturing and cryopreservation process to produce SuperNK™ ("SNK") cells. In vitro experiments performed by NKMAX have shown that SNK cells exhibit increased activity compared to the starting population of NK cells, as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved, maintaining high levels of cytotoxicity and activating receptor expression after thawing and reconstitution. NKGen Biotech believes SNK cells have the potential to benefit patients with neurodegenerative diseases, including Alzheimer's Disease ("AD") and Parkinson's disease ("PD"), and oncological diseases. Initial insights into the potential of SNK01, an autologous cell therapy candidate, in neurodegenerative disease come from compassionate use data involving three patients with AD and two patients with PD. Compassionate use refers to the use of an investigational medical product outside of a clinical trial in patients with a chronically or seriously debilitating disease who cannot be treated satisfactorily by an authorized medicinal product. Treatment of these five patients with SNK01 was associated with marked improvement in certain clinical symptoms typically associated with AD and PD, such as cognitive, vocal, and motor impairments.